Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug

 

Novo Nordisk Shares Fall 5.5% After Latest Trial Results for Its Next-Generation Weight Loss Drug

March 10, 2025 – Shares of Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) tumbled 5.5% in early trading on Monday after the company released clinical trial data for its next-generation weight loss drug. The results, while promising in some respects, fell short of investor expectations, raising concerns about the drug's potential market impact.

Trial Results: Mixed Signals for Investors

The Phase 2 trial for the new drug, currently known as Amycretide, demonstrated significant weight loss in patients over a 48-week period. However, the results did not exceed the efficacy of Novo Nordisk’s blockbuster drug Wegovy (semaglutide), which has dominated the weight loss market alongside Eli Lilly’s Zepbound (tirzepatide).

According to the company’s report, patients on Amycretide lost an average of 15% of their body weight, compared to the 15-17% weight reduction seen with Wegovy in similar trial durations. While the drug was generally well-tolerated, some participants reported increased gastrointestinal side effects, which could pose a challenge for broad adoption.

"The data confirms that Amycretide has strong potential, but we acknowledge that investors were hoping for a more pronounced improvement over existing treatments," said Lars Fruergaard Jørgensen, CEO of Novo Nordisk.

Market Reaction and Competitive Pressures

Novo Nordisk’s stock, which has seen a meteoric rise over the past two years thanks to surging demand for GLP-1 receptor agonists, dropped 5.5% following the announcement. Analysts had anticipated a more significant breakthrough, particularly given increased competition from Eli Lilly, Pfizer, and smaller biotech firms racing to develop more effective and longer-lasting obesity treatments.

"The weight loss drug market is incredibly lucrative, but expectations are sky-high," said Jefferies analyst Peter Welford. "Novo’s next-generation drug needs to clearly outperform Wegovy and Zepbound to maintain its leadership position, and today’s data doesn’t provide that level of confidence."

Regulatory and Commercial Outlook

Despite the market disappointment, Novo Nordisk remains optimistic about Amycretide’s commercial prospects. The company plans to proceed with Phase 3 trials later this year, aiming for regulatory approval by 2027. Meanwhile, demand for Wegovy continues to exceed supply, underscoring the enormous appetite for effective weight loss solutions.

As the weight-loss drug race intensifies, all eyes will be on how Novo Nordisk refines its strategy to stay ahead of competitors. Investors will be watching closely for updates on Amycretide’s development, as well as any potential advances in next-generation obesity treatments.

About Novo Nordisk
Novo Nordisk is a global pharmaceutical leader specializing in diabetes, obesity, and rare disease treatments. Founded in 1923 and headquartered in Denmark, the company has been at the forefront of developing GLP-1 receptor agonists, a class of drugs that has revolutionized obesity management.